Device Trial Radar · NCT04836546
Eversense® Non-adjunctive Use Post Approval Study
Last checked: Nov 19, 2026Latest source record: Aug 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
925
Planned (sponsor's estimate)
Start
Apr 13, 2021
Primary completion
Mar 31, 2026
Study completion Mar 31, 2026
Sponsor
- Lead sponsor
- Senseonics, Inc.Public (SENS)
- Sponsor type
- Industry
- First posted
- Apr 8, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a non-blinded, prospective, multi-center, single arm longitudinal cohort study (patient serving as their own control), to evaluate the effectiveness of diabetes with the Eversense CGM System non-adjunctively compared to self-monitoring of blood glucose (SMBG) using a blood glucose (BG) meter in participants with either Type 1 or Type 2 diabetes. Subjects will serve as their own control, with their baseline based on using SMBG to manage their diabetes for the first 6 months followed by using Eversense CGM System non-adjunctively for the second 6 months. Total follow-up duration is 12 months. The investigation will include both clinic visits and home use of Eversense CGM System. The nonadjunctive phase will have two sensors, up to 90-day duration, inserted sequentially. All care decisions specific to diabetes will be based on blood glucose (BG) values in the first phase and the Eversense CGM system values in the second phase.
Conditions
- Diabetes
Interventions
Blood glucose meterDevice
First phase: SMBG for 6 months
Eversense CGM SystemDevice
Second phase: CGM for 6 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of moderate and severe hypoglycemic and diabetic ketoacidosis eventsTime frame: First 6 months (phase 1) compared to second 6 months (phase 2)
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
LA Universal Research Center, Inc.
Los Angeles, California
Denver Endocrinology, Diabetes & Thyroid Center
Englewood, Colorado
CMR of Greater New Haven
Hamden, Connecticut
20 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.